• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Nidek receives CE Mark approval for two systems

Article

Nidek Co. Ltd. received CE Mark approvals for the Nidek EC-5000CXIII, a new and advanced refractive surgery laser system, and the Nidek CV-7000 phacoemulsification system.

With these approvals, the company aims to commercialize and market the new laser platform for refractive surgery throughout the world, particularly Europe and the Middle East. Nidek also would like to commercialize and further develop and expand its franchise in the cataract surgery marketplace in Europe, the Middle East, and Asia.

The new excimer laser platform is part of the Nidek Navex Quest System. The platform brings together advanced hardware modules, including 200-Hz eye tracking, torsion error detection and compensation, and multipoint laser delivery, along with proprietary software algorithms for customized refractive surgery.

The phacoemulsification system provides a high repetitive pulse mode for excellent operability and reduced thermal/heat generation, according to the company.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.